Search for other papers by Changwei Liu in
Google Scholar
PubMed
Search for other papers by Jingwen Wang in
Google Scholar
PubMed
Search for other papers by Yuanyuan Wan in
Google Scholar
PubMed
Search for other papers by Xiaona Xia in
Google Scholar
PubMed
Search for other papers by Jian Pan in
Google Scholar
PubMed
Search for other papers by Wei Gu in
Google Scholar
PubMed
Search for other papers by Mei Li in
Google Scholar
PubMed
Background Type 1 diabetes mellitus (T1DM) is an autoimmune disease occurring in the pancreatic islets. The disease can affect people of any age, but onset usually occurs in children or young adults, which accounts for 90% of diabetes in
Postgraduation Program in Medical Sciences: Endocrinology, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil
Search for other papers by Taís S Assmann in
Google Scholar
PubMed
Search for other papers by Mariana Recamonde-Mendoza in
Google Scholar
PubMed
Postgraduation Program in Medical Sciences: Endocrinology, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil
Search for other papers by Bianca M De Souza in
Google Scholar
PubMed
Postgraduation Program in Medical Sciences: Endocrinology, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil
Search for other papers by Daisy Crispim in
Google Scholar
PubMed
Introduction Type 1 diabetes mellitus (T1DM) is characterized by autoimmune destruction of pancreatic beta-cells by T lymphocytes and macrophages ( 1 ). The disease is usually diagnosed when over 80–90% of beta-cells have been destructed by
Search for other papers by Stavroula A Paschou in
Google Scholar
PubMed
Search for other papers by Nektaria Papadopoulou-Marketou in
Google Scholar
PubMed
Search for other papers by George P Chrousos in
Google Scholar
PubMed
Search for other papers by Christina Kanaka-Gantenbein in
Google Scholar
PubMed
Introduction Type 1 diabetes mellitus (T1DM) represents only around 10% of the diabetes cases worldwide, but occurs with increasing incidence much earlier in life. T1DM results from the autoimmune destruction of β cells of the endocrine
Search for other papers by M Boering in
Google Scholar
PubMed
Isala, Department of Internal Medicine, Zwolle, The Netherlands
Search for other papers by P R van Dijk in
Google Scholar
PubMed
Langerhans Medical Research group, Zwolle, The Netherlands
Search for other papers by S J J Logtenberg in
Google Scholar
PubMed
Department of General Practice, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Search for other papers by K H Groenier in
Google Scholar
PubMed
Search for other papers by B H R Wolffenbuttel in
Google Scholar
PubMed
Search for other papers by R O B Gans in
Google Scholar
PubMed
Langerhans Medical Research group, Zwolle, The Netherlands
Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Search for other papers by N Kleefstra in
Google Scholar
PubMed
Isala, Department of Internal Medicine, Zwolle, The Netherlands
Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Search for other papers by H J G Bilo in
Google Scholar
PubMed
Introduction Among type 1 diabetes mellitus (T1DM) patients, subcutaneous (SC) insulin administration is associated with low portal insulin concentrations and a consequent hepatic underinsulinization ( 1 ). Hepatic underinsulinization has been
Search for other papers by Xiuzhen Zhang in
Google Scholar
PubMed
Search for other papers by Dan Xu in
Google Scholar
PubMed
Search for other papers by Ping Xu in
Google Scholar
PubMed
Search for other papers by Shufen Yang in
Google Scholar
PubMed
Search for other papers by Qingmei Zhang in
Google Scholar
PubMed
Search for other papers by Yan Wu in
Google Scholar
PubMed
Search for other papers by Fengyi Yuan in
Google Scholar
PubMed
Introduction Amongst the background of the rising incidence of type 1 diabetes mellitus (T1DM) across the globe, public concern has reached a new high ( 1 ). Despite progress in diabetes care, as the leading cause of mortality in T1DM ( 2
Search for other papers by Yun Cai in
Google Scholar
PubMed
Search for other papers by Jieni Yan in
Google Scholar
PubMed
Search for other papers by Yong Gu in
Google Scholar
PubMed
Search for other papers by Heng Chen in
Google Scholar
PubMed
Search for other papers by Yang Chen in
Google Scholar
PubMed
Search for other papers by Xinyu Xu in
Google Scholar
PubMed
Search for other papers by Mei Zhang in
Google Scholar
PubMed
Search for other papers by Liping Yu in
Google Scholar
PubMed
Search for other papers by Xuqin Zheng in
Google Scholar
PubMed
Search for other papers by Tao Yang in
Google Scholar
PubMed
’ hyperthyroidism, while TGAb and TPOAb are more characteristic for HT, which is correlated with thyroidal damage and lymphocytic inflammation ( 1 , 2 ). Individuals with AITD may be associated with other autoimmune diseases, of which type 1 diabetes mellitus (T1
Search for other papers by Louise Færch in
Google Scholar
PubMed
Department of Cardiology, Department of Growth and Reproduction, Faculty of Health Sciences, Nephrology and Endocrinology H, Hillerød University Hospital, Dyrehavevej 29, DK-3400 Hillerød, Denmark
Search for other papers by Anders Juul in
Google Scholar
PubMed
Search for other papers by Ulrik Pedersen-Bjergaard in
Google Scholar
PubMed
Department of Cardiology, Department of Growth and Reproduction, Faculty of Health Sciences, Nephrology and Endocrinology H, Hillerød University Hospital, Dyrehavevej 29, DK-3400 Hillerød, Denmark
Search for other papers by Birger Thorsteinsson in
Google Scholar
PubMed
Objective
GH is implicated in the counter-regulatory response to hypoglycemia. We tested whether IGF1 levels are associated with occurrence of severe hypoglycemic events in patients with type 1 diabetes and whether the IGF1 concentration is influenced by glycemic control.
Methods
A total of 228 outpatients with type 1 diabetes were included in a post hoc analysis of a 1-year observational study on severe hypoglycemia. Serum total IGF1 was measured at entry into the study. The occurrence of severe episodes of hypoglycemia, mild symptomatic, and biochemical as well as hypoglycemia awareness status was assessed. Also patients were included in a multiple regression analysis to investigate the role of HbA1c in the IGF1 concentration.
Results
IGF1 levels were associated with neither severe hypoglycemia in the entire cohort (P=0.30) nor in any gender nor when confining the analysis to those with long-standing diabetes (>20 years) (n=112, P=0.68) and those with both long-standing diabetes and undetectable C-peptide (n=51, P=0.067). Levels of IGF1 were associated with neither mild symptomatic hypoglycemia (P=0.24) nor biochemical hypoglycemia (0.089) nor hypoglycemia awareness (P=0.16). At a multiple regression analysis, HbA1c was negatively associated with IGF1 (P=0.001).
Conclusion
In type 1 diabetes, circulating IGF1 levels are negatively associated with glycemic control. However, IGF1 levels were not associated with occurrence of hypoglycemia or hypoglycemia awareness in these patients.
Search for other papers by Marenao Tanaka in
Google Scholar
PubMed
Search for other papers by Tomohito Gohda in
Google Scholar
PubMed
Search for other papers by Nozomu Kamei in
Google Scholar
PubMed
Search for other papers by Maki Murakoshi in
Google Scholar
PubMed
Search for other papers by Tatsuya Sato in
Google Scholar
PubMed
Search for other papers by Mitsunobu Kubota in
Google Scholar
PubMed
Search for other papers by Michiyoshi Sanuki in
Google Scholar
PubMed
Search for other papers by Erika Ishiwata in
Google Scholar
PubMed
Search for other papers by Keisuke Endo in
Google Scholar
PubMed
Search for other papers by Yusuke Suzuki in
Google Scholar
PubMed
Search for other papers by Masato Furuhashi in
Google Scholar
PubMed
Background: Fatty acid-binding protein 4 (FABP4) is an adipokine that plays significant roles in the development of insulin resistance and atherosclerosis. High levels of soluble tumor necrosis factor receptors (TNFRs) including TNFR1 and TNFR2 are associated with renal dysfunction and increased mortality in patients with diabetes mellitus (DM). However, the association between circulating levels of FABP4 and TNFRs remains unclear.
Methods: We investigated the associations of FABP4 with TNFRs and metabolic markers in Japanese patients with type 1 DM (T1DM, n=76, men/women: 31/45) and type 2 DM (T2DM, n=575, men/women: 312/263).
Results: FABP4 concentration was positively correlated with levels of TNFR1 and TNFR2 in both patients with T1DM and those with T2DM. Multivariable regression analyses showed that there were independent associations of FABP4 concentration with body mass index (BMI) and estimated glomerular filtration rate (eGFR) after adjustment of age and sex in both patients with T1DM and those with T2DM. FABP4 concentration was independently associated with circulating levels of TNFR1 and TNFR2 after adjustment of the confounders in patients with T2DM but not in those with T1DM. Similarly, levels of TNFR1 and TNFR2 were independently associated with FABP4 concentration after adjustment of age, sex, systolic blood pressure, duration of DM and levels of eGFR, high-density lipoprotein cholesterol and C-reactive protein in patients with T2DM but not in those with T1DM.
Conclusion: FABP4 concentration is independently associated with levels of TNFRs in patients with DM, but the association is more evident in patients with T2DM than in those with T1DM.
Search for other papers by Ozlem Atan Sahin in
Google Scholar
PubMed
Search for other papers by Damla Goksen in
Google Scholar
PubMed
Search for other papers by Aysel Ozpinar in
Google Scholar
PubMed
Search for other papers by Muhittin Serdar in
Google Scholar
PubMed
Search for other papers by Huseyin Onay in
Google Scholar
PubMed
terms ‘type 1 Diabetes mellitus’ or ‘DM1’ was performed by O A, D G and M S Medline, Cochrane and PubMed abstracts were reviewed for relevance. No language and date of study restriction were applied to search strategy. Search to include the eligible
Search for other papers by Borros Arneth in
Google Scholar
PubMed
Introduction Type 1 diabetes mellitus (DM) is an autoimmune disease in which T-lymphocytes attack insulin-producing beta cells in the pancreas ( 1 ). During the later stages of this progressive disease, pancreatic beta cells are massively
